Class action alleges “no-generics” collusion by Gilead
Several activists and two employee benefit funds have sued Gilead and three other drugmakers for allegedly colluding to limit generic competition for treatment of human immunodeficiency virus.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10